
|Articles|February 6, 2006
FDA gives green light to anti-hepatitis B product
Advertisement
Cangene, one of Canada's largest biotechnology companies, announced that the FDA has approved HepaGam B for treatment following acute exposure to hepatitis B virus. HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pro-Life Groups Calling for Immediate Government Action on Abortion Pills
2
How Oral GLP-1 Medication Will Impact the Patient Medication Journey
3
IRA Drug Price Negotiations Threatening Pharmacies’ Financial Sustainability
4
Congressional Spending Bill to Include Key PBM Contracting Reform
5


















